These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9678917)

  • 1. Politics could hamper FDA reform.
    Fox JL
    Biotechnology (N Y); 1995 Nov; 13(11):1156. PubMed ID: 9678917
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA performance goals for approving drugs and biologics.
    Miller JD
    JAMA; 2009 Jul; 302(2):189-91. PubMed ID: 19584348
    [No Abstract]   [Full Text] [Related]  

  • 3. Will politics sidetrack FDA reform?
    Gatty B
    Formulary; 1995 Aug; 30(8):476, 475. PubMed ID: 10151736
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA "reform"?
    Feinstone SM; Lewis AM; Markoff LJ; Carbone K; Golding H
    Science; 1998 Jan; 279(5348):157-8. PubMed ID: 9446214
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA centennial.
    Kennedy D
    Science; 2006 Apr; 312(5770):19. PubMed ID: 16601155
    [No Abstract]   [Full Text] [Related]  

  • 6. The FDA is no place for politics.
    Nat Struct Mol Biol; 2006 May; 13(5):379. PubMed ID: 16738601
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulator under siege.
    Wadman M
    Nature; 2007 Dec; 450(7173):1143. PubMed ID: 18097370
    [No Abstract]   [Full Text] [Related]  

  • 9. What ails the FDA?
    Marcus DM
    N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962405
    [No Abstract]   [Full Text] [Related]  

  • 10. Confronting the future of the FDA.
    Serafini MW
    Natl J (Wash); 1996 Dec; 28(50):2704-5. PubMed ID: 10163877
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA reforms hampered by budget freeze.
    Jaffe S
    Lancet; 2012 Oct; 380(9852):1458-9. PubMed ID: 23115783
    [No Abstract]   [Full Text] [Related]  

  • 12. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
    Lurie P
    MedGenMed; 2006 Oct; 8(4):22. PubMed ID: 17415305
    [No Abstract]   [Full Text] [Related]  

  • 13. Cash infusion. White House seeks to boost oversight at FDA.
    Conn J
    Mod Healthc; 2008 Jun; 38(24):8-9. PubMed ID: 18661618
    [No Abstract]   [Full Text] [Related]  

  • 14. The big gap at the FDA.
    Stipp D
    Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract]   [Full Text] [Related]  

  • 15. The politics of FDA reform.
    Bérubé JE
    J Head Trauma Rehabil; 1998 Apr; 13(2):78-85. PubMed ID: 9575259
    [No Abstract]   [Full Text] [Related]  

  • 16. Review staff at FDA.
    Goldhammer A
    Science; 1997 May; 276(5313):661. PubMed ID: 9157539
    [No Abstract]   [Full Text] [Related]  

  • 17. Trump to nominate Scott Gottlieb as FDA commissioner despite industry links.
    Lenzer J
    BMJ; 2017 Mar; 356():j1339. PubMed ID: 28298314
    [No Abstract]   [Full Text] [Related]  

  • 18. US FDA feels the heat from Congressional hearings.
    Loewenberg S
    Lancet; 2008 May; 371(9624):1565-6. PubMed ID: 18476294
    [No Abstract]   [Full Text] [Related]  

  • 19. New leadership for the FDA.
    Lancet; 2002 Oct; 360(9341):1183. PubMed ID: 12401238
    [No Abstract]   [Full Text] [Related]  

  • 20. New "21st Century Cures" Legislation: Speed and Ease vs Science.
    Kesselheim AS; Avorn J
    JAMA; 2017 Feb; 317(6):581-582. PubMed ID: 28056124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.